接受自体干细胞移植的弥漫大B细胞淋巴瘤患者的微小残留病
研究纳入159例接受自体干细胞移植的复发/难治性弥漫大B细胞淋巴瘤患者,其中98例有采集干细胞样本、60例有移植后监测样本;采集干细胞样本中微小残留病阳性者无进展生存显著更差,移植后血浆微小残留病监测可识别即将复发。
要点
- 采集干细胞样本微小残留病阳性率23/98(23%),5年无进展生存13% vs 53%(P<.001)。
- 采集干细胞微小残留病阳性是多变量分析中无进展生存的显著预测因素(HR 3.7,P<.001)。
- 移植后血浆(而非外周血单个核细胞)微小残留病阳性与无进展生存更差相关(HR 3.0,P=.016)。
核心结论
- 在复发/难治性弥漫大B细胞淋巴瘤接受自体干细胞移植的患者中,采集干细胞样本检出微小残留病与极高的复发风险相关,作者认为这支持在此类患者中采用替代治疗策略或开展新巩固方案试验;移植后微小残留病监测可能有助于评估在分子学复发时早期启动治疗。
研究设计与样本
- 研究纳入159例接受自体干细胞移植的复发/难治性弥漫大B细胞淋巴瘤患者,其中98例有采集干细胞样本、60例有移植后监测样本;采用免疫球蛋白高通量测序检测采集干细胞样本、移植后外周血单个核细胞及血浆样本中的微小残留病;试验注册号NCT02362997。
主要发现
- 移植后中位随访60个月,5年无进展生存为48%。
- 采集干细胞样本中23/98(23%)检出微小残留病,与极差的无进展生存相关(5年无进展生存13% vs 53%,P<.001),总生存也更差(52% vs 68%,P=.05)。
- 采集干细胞微小残留病阳性预测进展和死亡的敏感度分别为36%、特异度为93%。
- 多变量分析中采集干细胞微小残留病阳性仍是无进展生存的显著预测因素(HR 3.7,P<.001)。
- 移植后监测中血浆(而非外周血单个核细胞)微小残留病检测可可靠识别即将复发者;血浆微小残留病阳性与无进展生存更差相关(HR 3.0,P=.016);从微小残留病检出至复发的中位提前时间为62天(范围0-518天)。
关键数值与推荐
- 采集干细胞样本微小残留病阳性率23/98(23%)。
- 采集干细胞微小残留病阳性者5年无进展生存13% vs 阴性者53%(P<.001),总生存52% vs 68%(P=.05)。
- 采集干细胞微小残留病阳性预测进展的敏感度36%、特异度93%。
- 采集干细胞微小残留病阳性预测无进展生存的多变量HR 3.7(P<.001)。
- 移植后血浆微小残留病阳性预测无进展生存的多变量HR 3.0(P=.016);中位提前时间62天(范围0-518天)。
临床怎么用
- 作者认为采集干细胞样本检出微小残留病与极高复发风险相关,支持在此类患者中采用替代治疗策略或开展新巩固方案试验;作者提出移植后微小残留病监测可能有助于评估在分子学复发时早期启动治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Improved biomarkers are required to guide the optimal use of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We hypothesized that minimal residual disease (MRD) identified using immunoglobulin high-throughput sequencing in apheresis stem cell (ASC) samples, post-ASCT peripheral blood mononuclear cell (PBMC), and plasma samples could predict relapse. We studied 159 patients with R/R DLBCL who underwent ASCT, of whom 98 had an ASC sample and 60 had post-ASCT surveillance samples. After a median post-ASCT follow-up of 60 months, the 5-year progression-free survival (PFS) was 48%. MRD was detected in of 23/98 (23%) ASC samples and was associated with very poor PFS (5-year PFS 13% vs 53%, P < .001) and inferior overall survival (52% vs 68%, P = .05). The sensitivity and specificity of ASC MRD positivity for progression and death were 36% and 93%, respectively. Positive ASC MRD remained a significant predictor of PFS in multivariable analysis (hazard ratio [HR], 3.7; P < .001). Post-ASCT surveillance MRD testing of plasma, but not PBMC samples, reliably identified patients with an impending relapse. A positive plasma MRD result was associated with inferior PFS (HR, 3.0; P = .016) in a multivariable analysis. The median lead time from MRD detection to relapse was 62 days (range, 0-518 days). In conclusion, the detection of MRD in ASC samples is associated with a very high risk of relapse, justifying alternative treatment strategies or trials of novel consolidation options in these patients. Furthermore, post-ASCT MRD monitoring may facilitate the evaluation of the early initiation of treatment at molecular relapse. This trial has been registered at www.clinicaltrials.gov as #NCT02362997.
引用
- Merryman RW, Redd RA, Taranto E, et al. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv. 2023. PMID: 36399518. doi:10.1182/bloodadvances.2022007706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。